Why the study?
Do ACE inhibitors and ARBs reduce all-cause and cardiovascular mortality in patients with hypertension?
Do ACE inhibitors and ARBs reduce all-cause and cardiovascular mortality in patients with hypertension?
In hypertensive populations, ACE inhibitors significantly reduce all-cause mortality whereas ARBs do not, suggesting ACE inhibitors should be considered ahead of ARBs.
The renin-angiotensin-aldosterone system is a key therapeutic target in hypertension. The latest meta-analysis of mortality reduction with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in hypertension features 158,998 patients from 20 contemporary hypertension trials. ACE inhibitors and ARBs significantly reduced relative risk for all-cause mortality by 5% (p = 0.032) and cardiovascular mortality by 7% (p = 0.018) in populations with a high prevalence of hypertension (≥66%). ACE inhibitors produced a 10% reduction in relative risk for all-cause mortality (p = 0.004) and a trend toward a 12% reduction in cardiovascular mortality (p = 0.051), whereas ARBs had no effect. On balance, mortality evidence suggests that in hypertension, ACE inhibitors should be considered ahead of ARBs, and ARBs restricted to patients intolerant of ACE inhibitors.
No takes yet. Share an insight, caveat, or question.
Ferrari et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: